EED-IN-3
EED-IN-3 is an orally active EED inhibitor. EED-IN-3 effectively inhibits PRC2 by binding to EED (IC50 = 0.62 μM for EED) and downregulates H3K27me3. EED-IN-3 can efficiently and selectively inhibit PC3 cells with the IC50 of 3.69 μΜ and could significantly suppress colony formation and migration. EED-IN-3 can be used for research on prostate cancer[1].
Product Specifications
CAS Number
3051817-48-9
UNSPSC
12352005
Target
Epigenetic Reader Domain; Histone Methyltransferase
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
COC1=CC=C(C=C1)C2=NN(C(C(C(NCCCOC(C)C)=O)=C2)=O)C3=CC=C(C=C3)OC
Molecular Formula
C25H29N3O5
Molecular Weight
451.51
References & Citations
[1]He ZX, et al. Design, synthesis, and biological evaluation of novel pyridazinone-based EED inhibitors for prostate cancer. Eur J Med Chem. 2025 Jun 9;296:117837.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
039039-ML650 100 µL
NOB1, CT (NOB1, ART4, NOB1P, PSMD8BP1, RNA-binding protein NOB1, Phosphorylation regulatory protein HP-10, Protein ART-4) (MaxLight 650) discontinued
Sign In for Pricing
View Details